SCHEMBL29586558

SCHEMBL29586558

Clc1ccc2c(c1)CN(c1cnc(-c3ncccn3)nc1)CC2

nearest known ligand 0.64

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
EED O75530 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21326135 1.00 EED (0.42) EED
SCHEMBL21326053 0.95 EED (0.42) EED
SCHEMBL29587359 0.84 GRIN2D (0.49) EED
SCHEMBL29587323 0.84
SCHEMBL21326073 0.84 GRIN2D (0.49) EED
SCHEMBL21326122 0.84
SCHEMBL29586870 0.83 EED (0.61) EED
SCHEMBL21326090 0.83 EED (0.61) EED
SCHEMBL21326077 0.82 EED (0.40) EED
SCHEMBL29586850 0.82 EED (0.40) EED

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109863145-B Novel tetrahydroisoquinoline and tetrahydronaphthyridine compounds for the treatment and prevention of hepatitis b virus infection 豪夫迈·罗氏有限公司 2022-04-12 CN claimed
CN-109863145-B Novel tetrahydroisoquinoline and tetrahydronaphthyridine compounds for the treatment and prevention of hepatitis b virus infection 豪夫迈·罗氏有限公司 2022-04-12 CN disclosed